EQT Life Sciences

Activity in this selectiondsm-firmenich-ventures-723f5931

By stage

Series B4

Series A1

Series C+1

Biotech5

Healthtech1

United States2

Germany1

Ireland1

Switzerland1

United Kingdom1

6 in this selection

Aug 11

Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia

$152MSeries B

Role not disclosed

Jun 24

Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients

$115MSeries A

Role not disclosed

Feb 11

Develops NEUROMARK, a minimally invasive solution to treat chronic rhinitis

Role not disclosed

Jan 29

Develops treatments to rejuvenate vision in the aging eye

$235MSeries B

Role not disclosed

Jan 20

Develops novel therapies for behavioral symptoms associated with Alzheimer's Disease

€51MSeries B

Role not disclosed

Jan 10

Develops inhaled therapies for severe respiratory diseases

$103MSeries B

Role not disclosed